1. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials

   • G. Nasti
   • A. Ottaiano
   • R. V. Iaffaioli

   Mini Review 24 March 2010 Pages: 209 - 218

2. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase

   • Andrea Réti
   • Éva Pap
   • Barna Budai

   Original Article 15 October 2009 Pages: 219 - 227

   

3. Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis

   • Su Jin Lee
   • Jeeyun Lee
   • Young Suk Park

   Original Article 10 October 2009 Pages: 229 - 235

   

4. Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines

   • Yoshitsugu Horio
   • Hirotaka Osada
   • Yoshitaka Sekido

   Original Article 07 October 2009 Pages: 237 - 243

   

5. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents

   • Kosalaram Goteti
   • C. Edwin Garner
   • Patrick J. Brassil

   Original Article 16 October 2009 Pages: 245 - 254

   

6. Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells

   • Aleksandar Radujkovic
   • Stefan Fruehauf
   • Julian Topaly

   Original Article 28 October 2009 Pages: 255 - 264

   

7. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report

   • Daniel P. Greene
   • James Stuart Ferriss
   • Amir A. Jazaeri

   Original Article 21 October 2009 Pages: 265 - 267

8. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy

   • Kaori Fujimoto-Ouchi
   • Fumiko Sekiguchi
   • Kazushige Mori

   Original Article 11 November 2009 Pages: 269 - 276

   

9. Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo

   • Xiaolei Ye
   • Wu Zhou
   • Yisheng Lai

   Original Article 30 March 2010 Pages: 277 - 285

   

10. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

    • Steven J. Cohen
    • Mark M. Zalupski
    • Evan M. Hersh

    Original Article 24 October 2009 Pages: 287 - 294

    

11. Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer

    • Trine Zeeberg Buch-Hansen
    • Lise Bentzen
    • Lisa Sengeloev

    Original Article 31 October 2009 Pages: 295 - 301

    

12. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats

    • Karol L. Thompson
    • Barry A. Rosenzweig
    • Eugene H. Herman

    Original Article 14 November 2009 Pages: 303 - 314

    

13. Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats

    • Valentina K. Todorova
    • Yihong Kaufmann
    • V. Suzanne Klimberg

    Original Article 08 November 2009 Pages: 315 - 323

    

14. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide

    • Kelley A. Sookraj
    • Wilbur B. Bowne
    • Matthew R. Pincus

    Original Article 25 February 2010 Pages: 325 - 331

    

15. Can the 2-¹³C-uracil breath test be used to predict the effect of the antitumor drug S-1?

    • Yukimoto Ishii
    • Shigeru Suzuki
    • Satoshi Asai

    Original Article 18 November 2009 Pages: 333 - 343

    

16. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment

    • Christopher J. Sweeney
    • Chris Takimoto
    • Scot C. Remick

    Original Article 13 November 2009 Pages: 345 - 356

    

17. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

    • Brett E. Houk
    • Carlo L. Bello
    • Robert J. Motzer

    Original Article 05 December 2009 Pages: 357 - 371

    

18. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer

    • Sun Jin Sym
    • Min-Hee Ryu
    • Yoon-Koo Kang

    Original Article 21 November 2009 Pages: 373 - 380

    

19. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors

    • Yun Jung Choi
    • Jin Kyung Rho
    • Jae Cheol Lee

    Original Article 18 November 2009 Pages: 381 - 388

    

20. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors

    • F. Caponigro
    • D. Lorusso
    • S. Comis

    Original Article 22 November 2009 Pages: 389 - 394

    

21. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer

    • Emmanuel Mitry
    • Pascal Hammel
    • Eric Raymond

    Clinical Trial Report 04 April 2010 Pages: 395 - 403

    

22. Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?

    • N. A. Helsby
    • W. Y. Lo
    • G. R. Laking

    Short Communication 17 February 2010 Pages: 405 - 407

23. Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy

    • Anilkumar Katta
    • Mark J. Fesler
    • John M. Richart

    Short Communication 05 March 2010 Pages: 409 - 412